Victoza (liraglutide)
- Region
- 🇪🇺 EU
- Active substance
- liraglutide
- Company
- Novo Nordisk A/S
- Status
- Authorised
- Therapeutic area
- Diabetes Mellitus, Type 2
- CHMP opinion
- Thu 23 Apr 2009
- EU approval
- Tue 30 Jun 2009
- Application
- EMEA/H/C/001026
- ATC
- A10BJ02
- Official record
- www.ema.europa.eu
Indication
Victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied.
Regulatory milestones
Victoza: shortage ongoing
Pre-filled pen; Alternatives available: Yes · source
Same substance in other markets
- 🇪🇺 Ablymico Authorised · STADA Arzneimittel AG
- 🇪🇺 Liraglutide STADA Authorised · STADA Arzneimittel AG
- 🇪🇺 Saxenda Authorised · Novo Nordisk A/S
- 🇪🇺 Xultophy Authorised · Novo Nordisk A/S
Follow Victoza
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.